The Therapeutic Proteins and Oral Vaccines Market Size is valued at 228.99 Million in 2022 and is predicted to reach 436.26 Million by the year 2031 at a 7.8 % CAGR during the forecast period for 2023-2031.
Therapeutic proteins are genetically engineered proteins that have a wide range of treatment applications. Therapeutic proteins are mainly prepared for pharmaceutical use. Oral vaccines are biologically prepared products, which are used in treating or preventing various infectious diseases. The increasing number of pharmaceutical drug developments or innovations is expected to drive the growth of the therapeutic protein and oral vaccine market in the near future.
Major driving factors of the therapeutic proteins and oral vaccines market are the increasing need for therapeutic proteins and oral vaccines, high prevalence of cancer diseases, rising number of clinical trials, increasing investments by key players for the development of promising therapies. Furthermore, advanced medical technologies, growth in the population, and a growing number of health-conscious people are enhancing the growth of the therapeutic proteins and oral vaccines market. However, the high price of devices, complex procedures, lack of strict government laws are restraining the growth of this market.
Market Segmentation
The therapeutic proteins and oral vaccines market is segmented into Drug Class, Distribution Channels, Applications, and regions. The Drug Class segment is further bifurcated into Therapeutic Proteins and Oral Vaccines. Therapeutic Proteins are subdivided into Therapeutic Proteins, Growth Factors, Fusion Proteins, Monoclonal Antibodies, Hormones, Coagulation Factors, and Other Therapeutic Proteins. While, Oral Vaccines are subdivided into Live Attenuated Vaccine, Inactivated Vaccine, Recombinant Vaccine, and Other Oral Vaccines. In the coming future, therapeutic proteins will be in high scope due to their effective and fast results and rise in therapy innovations. By Distribution Channels, the market is segmented into Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies. Hospital Pharmacies will upscale the market of therapeutic proteins and oral vaccines over the forecast period. In terms of Applications, the market can be divided into Oncology, Hematology, Immunology, Endocrinology, Infectious Disease, Cardiovascular Disease, and Other Applications. Oncology and Infectious diseases are the fastest-growing segments of this market due to the increasing prevalence of cancer and infectious diseases. Based on the region, the therapeutic proteins and oral vaccines market is divided into North America, Europe, Asia-Pacific, Latin America, and the Middle East and Africa. North America followed by Europe holds the maximum share of this market due to increased research and development expenditure, presence of significant market players and fast adaption of advanced technologies.
Competitive Landscape
Some Major Key Players In The Therapeutic Proteins and Oral Vaccines Market:
- Abbott Laboratories,
- Amgen, Inc.,
- Biogen, Inc.,
- Eily, Lilly, and Company,
- Hoffmann-La Roche,
- Johnson and Johnson,
- Merck & Co.,
- Novo Nordisk,
- Pfizer, Inc.,
- Sanofi S.A.,
- Serum Institute of India Pvt. Ltd.,
- Emergent Biosolutions Inc.,
- TransAlgae,
- MigVax Ltd,
- Lumen Bioscience, Inc.,
Therapeutic Proteins and Oral Vaccines Market Report Scope
|
Report Attribute |
Specifications |
|
Market Size Value In 2022 |
USD 228.99 Million |
|
Revenue Forecast In 2031 |
USD 436.26 Million |
|
Growth Rate CAGR |
CAGR of 7.8 % from 2023 to 2031 |
|
Quantitative Units |
Representation of revenue in US$ Million and CAGR from 2023 to 2031 |
|
Historic Year |
2019 to 2022 |
|
Forecast Year |
2023-2031 |
|
Report Coverage |
The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
|
Segments Covered |
By Drug Class, By Distribution Channel, By Application |
|
Regional Scope |
North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
|
Country Scope |
U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico ;The UK; France; Italy; Spain; China; Japan; India; South Korea; South East Asia; South Korea; South East Asia |
|
Competitive Landscape |
Abbott Laboratories, Amgen, Inc., Biogen, Inc., Eily, Lilly, and Company, F. Hoffmann-La Roche, Johnson and Johnson, Merck & Co., Novo Nordisk, Pfizer, Inc., Sanofi S.A., Serum Institute of India Pvt. Ltd., Emergent Biosolutions Inc., TransAlgae, MigVax Ltd, Lumen Bioscience, Inc., and Other Prominent Players. |
|
Customization Scope |
Free customization report with the procurement of the report, Modifications to the regional and segment scope. Particular Geographic competitive landscape. |
|
Pricing And Available Payment Methods |
Explore pricing alternatives that are customized to your particular study requirements. |
